

LACHMAN CONSULTANT SERVICES, INC.
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590
(516) 222-6222 • FAX (516) 683-1887

7/7/04 JUL 7 19:21

July 7, 2004

OVERNIGHT COURIER 7/7/04

Dockets Management Branch
Food and Drug Administration
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, MD 20852

**WITHDRAWAL OF CITIZEN PETITION
DOCKET NO. 2003P-0505/CP1**

Reference is made to the ANDA suitability petition submitted on October 31, 2003 on behalf of a client, pursuant to Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act ("the FDC Act"), 21 U.S.C. § 355(j)(2)(C), and 21 C.F.R. §§ 10.20, 10.30, and 314.93 to request that the Commissioner of the Food and Drug Administration make a determination that an abbreviated new drug application (ANDA) may be submitted for the following drug product, Acetaminophen, Caffeine and Orphenadrine Citrate Tablets, in two strengths of 770 mg / 60 mg / 50 mg and 385 mg / 30 mg / 25 mg, respectively.

Based on a conversation with a representative of the Office of Generic Drugs, and after consultation with our client, we respectfully request that this petition be withdrawn without prejudice to refiling.

Sincerely,



Robert W. Pollock *PK*
Vice President
Lachman Consultant Services, Inc.
1600 Stewart Avenue
Westbury, NY 11590

RWP/pk

cc: Cecelia Parise, Office of Generic Drugs

M24P4189

2003P-0505

WDL 1